Cite
HARVARD Citation
Tica, J. et al. (n.d.). 119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated. Open forum infectious diseases. pp. S187-S188. [Online].